Zhu, Andrew X.
Abbas, Alexander R.
de Galarreta, Marina Ruiz http://orcid.org/0000-0001-9666-8416
Guan, Yinghui
Lu, Shan
Koeppen, Hartmut
Zhang, Wenjun
Hsu, Chih-Hung
He, Aiwu Ruth
Ryoo, Baek-Yeol
Yau, Thomas
Kaseb, Ahmed O.
Burgoyne, Adam M.
Dayyani, Farshid http://orcid.org/0000-0002-4970-5189
Spahn, Jessica
Verret, Wendy
Finn, Richard S.
Toh, Han Chong
Lujambio, Amaia http://orcid.org/0000-0002-2798-1481
Wang, Yulei http://orcid.org/0000-0002-9057-9786
Article History
Received: 27 July 2021
Accepted: 11 May 2022
First Online: 23 June 2022
Competing interests
: A.X.Z. received consulting fees from Bayer, Eisai, Eli Lilly, Exelixis, F. Hoffmann–La Roche, Merck, Gilead, Sanofi Aventis and Sirtex. M.R.G. has received grant support from Genentech. A.R.A., Y.G., S.L., H.K., J.S., W.V. and Y.W. are employees of Genentech and hold stock or other ownership interests in F. Hoffmann–La Roche. W.Z. is an employee of Roche Tissue Diagnostics and holds stock and other ownership interests in Roche. C.-H.H. received consulting fees from AstraZeneca, Eli Lilly and Roche, and received honoraria from Bristol-Meyers Squibb, Eisai, Merck Sharp & Dohme, Ono Pharmaceutical and Roche. A.R.H. has received research funding from Genentech and Merck, and has been on a speakers’ bureau for Eisai, BMS and Exelixis. B.-Y.R. has nothing to declare. T.Y. has received honoraria and consulting fees from Bristol-Myers Squibb. A.O.K. has received honoraria from Bayer Health, Bristol-Myers Squibb, Eisai, Exelixis, Genentech/Roche and Merck; has received consulting fees from Bayer Health, Bristol-Myers Squibb, Eisai, Exelixis, Genentech/Roche and Merck; has received institutional research funding from Adaptimmune, Bayer/Onyx, Bristol-Myers Squibb, Genentech, Hengrui Pharmaceutical and Merck; and travel, accommodation and other expenses support from Bayer/Onyx, Bristol-Myers Squibb, Exelixis and Merck. A.M.B. has received consulting fees from Deciphera, Exelixis and Genentech. F.D. has received consulting fees from Genentech/Roche, Array BioPharma, Exelixis, Eisai, QED Therapeutics and Signatera; has been on a speakers’ bureau for Genentech/Roche, Amgen, Eisai, Ipsen, Exelixis, Sirtex Medical, Deciphera, Natera and Servier; has received institutional research funding from Bristol-Myers Squibb, AstraZeneca, Merck, Genentech, Taiho Pharmaceutical, Exelixis and Ipsen; and has an immediate family member who is an employee of Roche Diagnostics. R.S.F. has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, F. Hoffmann–La Roche/Genentech, Lilly, Merck, Novartis and Pfizer; has received institutional research funding from Bayer, Bristol-Myers Squibb, Eisai, Lilly, Merck, Novartis, Pfizer and F. Hoffmann–La Roche/Genentech; and has provided expert testimony for Novartis. H.C.T. has received honoraria from Roche, MSD Merck, Ipsen and AstraZeneca. A.L. has received consulting fees from AstraZeneca and research funding from Pfizer.